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Proteases play a pivotal role in epidermal differentiation and desquamation. Separation of a total protein extract
from human reconstructed epidermis by two-dimensional gel electrophoresis and subsequent peptide analysis of
a specific protein spot identiﬁed a new protein exhibiting similarities with the retroviral aspartic protease family.
Cloning of the corresponding full-length cDNA revealed an open reading frame encoding for a new protease of 343
amino acids, containing a putative aspartic protease catalytic domain. We named this protein Skin ASpartic Pro-
tease (SASPase). RT-PCR and northern blot analysis of various human tissues revealed that SASPase was spe-
cifically expressed within the epidermis. Immunohistochemical analysis showed a particularly intense expression
restricted to the granular layers, whereas in diseased skin, its expression was changed. Western blot analysis,
using a monoclonal antibody, revealed the expression of two forms of the enzyme: a 28 kDa putative proform and
the active 14 kDa form. Recombinant truncated SASPase (SASP28) was generated from a prokaryotic expression
system in Escherichia coli as a fusion protein with GST. SASP28 degraded insulin and to a lesser extent casein with
a pH optimum of 5. As seen for retroviral proteases, an auto-activation processing was evidenced, generating a 14
kDa protein (SASP14). Site-directed mutagenesis inhibited auto-activation of the enzyme. Indinavir, a potent HIV
protease inhibitor used in AIDS therapy, had a significant inhibitory effect on rSASPase auto-activation, which
could explain its side effects on skin.
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The epidermis is a multilayered squamous epithelium, com-
posed mainly of keratinocytes that migrate from the basal
layer to the skin surface. During migration, they undergo
what is generally described as epidermal differentiation,
i.e., keratinocytes are transformed into corneocytes. These
cornified cells form the uppermost layer of the skin, the
stratum corneum, which provides the protective barrier be-
tween our organism and the environment. Corneocytes are
eventually eliminated by a process called desquamation.
Throughout the process of keratinocyte differentiation and
particularly during the desquamation process, proteases
are important players.
Various proteases have been associated with the differ-
entiation-related processing of pro-filaggrin to filaggrin and
eventually its degradation to amino acids (aa), also known
as natural moisturizing factors (NMF), which contribute to
the self-hydration capacity of the stratum corneum. Calpain
I, a well-known calcium-activated neutral cysteine protease,
is known to process pro-filaggrin (Resing et al, 1993). Two
recent papers identified keratinocyte Matriptase/MT-SP1, a
type II trans-membrane serine protease, as being an es-
sential component of the pro-filaggrin-processing pathway
and a key regulator of terminal epidermal differentiation (List
et al, 2002, 2003). The further processing of filaggrin has
been attributed to a serine protease of unknown identity
termed pro-filaggrin endopeptidase 1 (Resing et al, 1995).
During filaggrin proteolysis, an NH2-terminal S-100 protein
is released, possibly under the control of furin, belonging to
the pro-protein convertase family of Ca2þ -dependent se-
rine proteases (Pearton et al, 2001). Keratinocyte differen-
tiation has been assimilated to a particular apoptosis where
the recently discovered and tissue-specific caspase,
caspase 14, plays a part in differentiation and skin barrier
formation (Van de Craen et al, 1998; Lippens et al, 2000;
Rendl et al, 2002; Mikolajczyk et al, 2004). Another charac-
teristic feature of keratinocyte terminal differentiation is the
formation of the cornified envelope by the cross-linking of
precursor proteins under the action of transglutaminases.
Two of these require proteolytic activation for their activity.
Transglutaminase1 is activated by Calpain (Kim and Bae,
1998) and transglutaminase 3, which exists as a pro-
enzyme, by an unknown protease (Kim et al, 2001).
Desquamation requires the degradation of corn-
eodesmosomes, modified desmosomal structures that ac-
count for the adhesion of corneocytes in the stratum
corneum (Serre et al, 1991). Two serine proteases of the
Kallikrein family, Kallikrein 5 and Kallikrein 7, have been
described to play key roles in this event (Egelrud and
Lundstrom, 1991; Hansson et al, 1994; Brattsand and
Egelrud, 1999; Simon et al, 2001; Kuwae et al, 2002; Ko-
matsu et al, 2003; Caubet et al, 2004). Recently, proteases
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with an acidic pH optimum were identified in the stratum
corneum and associated with desquamation. They belong
either to the aspartic acid protease family, like cathepsin D
(Horikoshi et al, 1998), or to the cysteine protease family,
like cathepsin L2 and like the partially characterized ‘‘stra-
tum corneum cathepsin L-like’’ (Bernard et al, 2003). The
lysosomal cysteine proteases, cathepsin L (Tobin et al,
2002) and cathepsin C, also named dipeptidyl amino-
peptidase I (Toomes et al, 1999), are also described as be-
ing related to the process of keratinocyte differentiation.
Although these three main proteases families are constitu-
tively expressed in the epidermis, the expression of metal-
loproteinases is more related to inflammation and to injured
tissue. An exception is the expression of MMP19 in normal
epidermal layers (Sadowski et al, 2003). Finally, another
important role of proteases in epidermal physiology is ex-
emplified by trypsin-like protease in the activation of Pro-
teinase-activated receptor-2, which has been demonstrated
to be an essential step for melanosome transfer from me-
lanocytes to keratinocytes (Steinhoff et al, 1999; Scott et al,
2001).
We applied a proteomic strategy to further improve our
understanding of epidermal differentiation and the specific
role of proteases in this process. Here, we describe the
identification and characterization of a new member of the
aspartic proteases family, a unique epidermal retroviral-like
protease, which we named Skin ASpartic Protease (or SAS-
Pase).
Results
Epidermal SASPase: sequence analysis and putative 3D
structure Analyzing differentiation-related protein expres-
sion, a protein spot with an apparent MW of 14 kDa and an
isoelectric point of 5.8 was sequenced (Fig 1). Each of the
four peptide sequences obtained had a 100% match with
the sequence of a putative protein identified as a product of
the gene ‘‘munu’’, also known as protein FLJ25084 (Fig 2A),
a gene product that maps to chromosome 2 at 2p13.3 at
locus 151516. This gene is predicted to cover 2356 bp and
to contain no intron. The putative ‘‘complete’’ protein is 343
aa long (37 kDa, pI 5.3). An alternative ‘‘short’’ form starting
at methionine 85 is also proposed in the databases (259 aa,
28.5 kDa, pI 5.22). Using prosite search (http://us.expasy.
org/prosite/), an aspartyl protease with a retroviral-type sig-
nature was found, with aspartic acid 212 as the putative
active aa site. Prosite search predicted a putative N
myristoylation domain (aa 1–7) and a putative dileucine
site (aa 50–51). Some putative N-glycosylation, sulfatation,
phosphorylation, myristoylation, and amidation sites were
also detected (Fig 2A). From aa 56 to 77, a putative trans-
membrane domain was detected with the SOSUI algorithm
(http://sosui.proteome.bio.tuat.ac.jp/). Based on a BLAST
search, orthologous genes were found in Mus musculus and
Rattus norvegicus. Alignment with the mouse ortholog (data
not shown) demonstrated a high degree of conservation
during evolution. The homology at the aa level was 87%
using the complete sequence and even higher in the pu-
tative active site region.
The program 3D-PSSM (Kelley et al, 2000) was used to
calculate the putative 3D structure of SASP14 (Fig 2B, C).
The equine anemia virus (EIAV) protease structure was de-
fined as the best template for the simulation (d1fmb pdb
file). The percentage of identity between SASP14 and EIAV
PR was 23% and this increases to 47% in the 15 aa sur-
rounding the active site. The calculated percentage of cer-
tainty for the structure was 80%.
SASPase mRNA is expressed exclusively within epider-
mis Northern blot analysis of SASPase expression with a
commercial mRNA blot from Origene (Rockville, Maryland)
revealed that human SASPase was expressed mainly as a
transcript of 1550 bp (Fig 3) that was different from the size
deduced from the genome (2356 bp), but similar in size to
clone AK057813 (isolated from cerebellum, 1571 bp) from
a cap-selected library that appears to be 50 incomplete. Its
expression was clearly detected in the skin and to a lesser
extent in the brain. SASPase expression was undetectable
in the eleven other tissues. Similar results were obtained in a
PCR study with a Rapid-scan cDNA kit from Origene (data
not shown).
SASPase expression of normal and diseased human
skin Western blot analysis of extracts obtained from nor-
mal and reconstructed human epidermis with the mono-
clonal antibody SASP7H9 revealed the presence of the 28
kDa and 14 kDa form of SASPase in both extracts (Figs 4A,
1ab and 2ab). Whereas the 14 kDa represents the activated
form of SASPase, the 28 kDa might be considered as the
epidermal SASPase pro-form. The fact that in the upper-
most layers of the epidermis the pro-form no longer exists
(Fig 4A, 4ab) indicates that its activation process seems to
be related to keratinocyte differentiation. The incomplete
processing observed in psoriatic epidermis, where the in-
activated form persists throughout the stratum corneum
(Figs 4, 3ab), supports this hypothesis.
Figure 1
Location of Skin ASpartic Protease (SASPase) in a 2D elect-
rophoresis gel of protein extracts of reconstructed human epider-
mis. Extracts (4 mg protein) from reconstructed epidermis were
separated by 2D electrophoresis. Proteins were stained with Amido
Black. The newly discovered human protease ‘‘SASPase’’ has a cal-
culated MW of 14 kDa and an isoelectric point (pI) of 5.8 (spots rep-
resenting known proteins are listed with their respective names).
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All sections of normal human skin showed a strong lo-
calized expression of SASPase in the granular layer of the
epidermis (Fig 4B). SASPase was also detected in the inner
root sheath of hair follicles (Fig 4C). In the psoriatic sample
(Fig 4D, E), SASPase expression persisted throughout the
stratum corneum, confirming indirectly its high expres-
sion level detected by western blot analysis of psoriatic
squames. In skin with ulceration, a strong positive staining
was observed in the stratum granulosum of intact epidermis
(Fig 4F) as in healthy skin. Expression was, however, almost
absent in the ulcerated part (Fig 4G).
SASPase is an auto-activated aspartic protease Due to
the ambiguity of the translation initiation codon used in vivo,
two recombinant GST fusion proteins were produced, cor-
responding to the 37 kDa form, SASP37 and to the 28.5 kDa
form, SASP28. SASP37 production gave a poor yield
(data not shown), probably due to the known difficulties
in producing proteins with trans-membrane domains in
Escherichia coli. Therefore, we used SASP28 as the re-
combinant SASPase in our experiments.
We used a highly sensitive, fluorescence-based protease
assay to investigate rSASPase catalytic activity. This assay
Figure2
Skin ASpartic Protease (SASPase) se-
quence and putative 3D structure. (A)
Sequence. Nucleotide sequence coding
for human SASPase aligned with its de-
duced amino acid (aa) sequence. Dotted
lines underline aa indicating the prosite
signature of a retroviral-type aspartyl pro-
tease. Active site aspartic acid is in bold.
Sequences obtained from Edman se-
quencing after trypsin digestion of the
isolated 2D spot are boxed with double
lines. A putative di-leucine domain and
transmembrane region are underlined
with double lines or a single bold line, re-
spectively. A single nucleotide poly-
morphism has been detected at aa
position 49 replacing threonine (T) by Ala-
nine (A). Two methionines are highlighted
with bold letters and correspond to two
putative start codons for SASPase. (B–C)
Modelization. The program 3D-PSSM was
used to calculate the putative 3D struc-
ture of SASP14. The equine anemia virus
protease structure was calculated as be-
ing the best template for the simulation
(d1fmb pdb file). The calculated certainty
of the structure was 80% and evaluated
to be ‘‘good’’ following the software cri-
teria. The structure was represented with
the swiss pdb viewer v3.7 software (B)
(http://www.exspasy.ch.spdbv) and 3D
rendering was improved with the Pov ray
software (C). The active site aspartic acid
(D24) is highlighted with an arrow.
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allowed continuous, real-time measurement of protease
activity by using the intra-molecular quenched BODIPY FL-
labeled casein as the substrate. Incubation of rSASPase
with the quenched casein substrate (data not shown) results
in a time-dependent increase of fluorescence at a pH
optimum of 5, indicating that rSASPase hydrolyzed casein.
Further analysis revealed that rSASPase primarily hy-
drolyzed one bond in the oxidized B chain of insulin
at Glu13 Ala14. Minor cleavages were noted at Leu15
Tyr16 and Tyr16 Leu17 (data not shown).
SDS-PAGE of rSASPase fusion protein performed after
its incubation at pH 5, and 371C, resulted in a time-related
generation of a low-molecular-weight protein (Fig 5A). Ed-
man sequencing and mass spectrometry of this auto-cat-
alytically generated SASPase fragment identified a protein
composed of 136 aa, an MW of 14.8 kDa, and an isoelectric
point of 5.2 (SASP14). The major cleavage sites were at
Asn190 Ser191 and Glu326 Leu327. Interestingly, after the
removal of the N-terminal auto-activation site, the enzyme
used a new cleavage site at Ala167 Leu168 (data not
shown). The fact that active site-directed mutations (re-
placement of active site aspartic acid by either alanine or
glutamic acid) resulted in the loss of auto-activation capac-
ities (Fig 5B) indicated that SASPase was a true member of
the aspartic proteases family, and that aspartic acid in po-
sition 212 (D212) was the key aa of its active site. The dif-
ferent putative SASPase forms are schematically presented
in Fig 5C.
Indinavir inhibits SASPase auto-activation Among the
five distinct HIV protease inhibitors tested on the auto-ac-
tivation capacity of SASPase, only indinavir was able to
inhibit this process considerably (Fig 6). Interestingly, peps-
tatine, the classical inhibitor of the aspartic proteases, did
not affect the process of auto-activation at all even when
used at 1 mM. DAN and EPNP, two other classical aspartic
protease inhibitors (Chang et al, 1976), did not inhibit the
autoactivation process even when used at 0.1 mM con-
centrations (data not shown).
Discussion
After 2D electrophoresis of protein extracts of reconstruct-
ed human epidermis, we identified a 14 kDa protein spot
Figure 2
Continued.
Figure 3
Skin ASpartic Protease (SASPase) Northern blot study in different human tissues. Human multiple tissue mRNA blot (Origene), 2 mg of
poly(A)  per lane from tissues indicated above each lane. The calculated mRNA size of SASPase is indicated on the left. The blot was hybridized
with a human 1.026 kb radiolabeled SASPase probe.
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corresponding to an unknown human aspartic protease,
which we named Skin Aspartic Protease due to its abun-
dant expression in keratinocytes. The peptide sequences
obtained matched with the sequence of a putative protein
identified as a product of gene ‘‘munu’’ that mapped to
chromosome 2 at 2p13.3 at locus 151516. An aspartyl pro-
tease with a retroviral-type signature could be predicted
from the protein sequence. Production of a recombinant
28 kDa form of the enzyme permitted us to demonstrate
that this particular recombinant form undergoes an auto-
activation process at pH 5. This auto-activation process is a
common feature of retroviral aspartic proteases and thus
SASPase is related to this family. Site-directed mutagenesis
of the putative-active site aspartic acid definitively demon-
Figure4
Immunodetection of Skin ASpar-
tic Protease (SASPase) in normal
and diseased skin. Western blot
(A): Two repetitions (a, b) were made
for each sample. 1, normal human
epidermis extract; 2, reconstructed
epidermis 13 d; 3, psoriatic stratum
corneum extract; and 4, normal
non-plantar stratum corneum ex-
tract. Immunohistochemistry (B–G)
was performed on paraffin sections
of normal and diseased skin using
the monoclonal antibody SASP7H9
as the primary antibody. The posi-
tive staining observed was mostly
cytoplasmic and occasionally nucle-
ar in the stratum granulosum of nor-
mal skin (B) and in the inner root
sheath of hair follicles (C). In psoria-
sis sample (D, E), increased staining
was present in the stratum corn-
eum. In skin with ulceration (F, G),
strong positive staining was ob-
served in the stratum granulosum
of the intact area (F) but was mark-
edly reduced immediately adjacent
to the ulcer (G). SC, stratum corn-
eum; E, epidermis; D, dermis.
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strated that SASPase was a true new member of the aspar-
tic protease family. Another common feature of retroviral-
like proteases is the necessity of a homodimeric association
for the formation of the active site pocket. Complementary
experiments demonstrated that the low MW SASPase
(14 kDa) was probably able to form homodimeric-active
associations (data not shown). The use of the monoclonal
antibody in healthy and diseased human skin revealed a strong
SASPase expression restricted to the granular layer of normal
epidermis and the inner root sheath of the hair follicle, whereas
in psoriatic epidermis, expression persists throughout the
parakeratotic stratum corneum. In ulcerated skin, SASPase
expression was normal in the adjacent area of the ulcer and
absent in the affected part. Its absence and modified ex-
pression pattern in certain skin pathologies will be further
investigated and might contribute toward the elucidation of
the physiological role of SASPase in the epidermis.
The above results and the detection of SASPase (14 kDa
form) by western blot analysis in the stratum corneum
extracts of normal human skin might be contradictory,
however, since it is well known that many antigens are
masked within the lipid environment of the stratum corn-
eum. Labeling of SASPase within psoriatic stratum corneum
could reflect an impaired maturation of the enzyme within
the stratum corneum.
Further western blot analysis during the reconstruction of
epidermis revealed that SASPase expression is related to
keratinocyte differentiation (data not shown), in particular,
its activation, i.e., the conversion of the 28 kDa proform into
the active 14 kDa protein. Thus, our monoclonal antibody
seems to label preferentially, if not exclusively, the activated
form of SASPase. The putative 37 kDa form, predicted from
the database DNA sequence, could not be detected in ep-
idermal extracts.
Aspartic proteases are suggested to have evolved by
gene duplication and fusion of an ancestral protein with the
size of a pepsin lobe (Tang et al, 1978). Retroviruses, e.g.,
HIV, are known to express a ‘‘half-sized’’ aspartic protease,
which becomes activated after dimerization (Wlodawer and
Gustchina, 2000). Although the hypothesis exists that re-
troviral proteases might be fossils of ancestral dimeric
aspartic proteases (Pearl and Taylor, 1987), it is generally
more accepted that aspartic proteases have evolved by
gene duplication and fusion (Tang et al, 1978; Lin et al,
1992). The discovery of SASPase with its unique properties
of auto-activation and subsequent dimerization to form an
active enzyme provides new arguments in favor of an an-
cestral eucaryotic protease being at the origin of retroviral
proteases.
Most of the human endogenous retroviral (HERV) gen-
ome has been acquired 10–100 million years ago and con-
stitutes between 0.1% and 1% of our germ line DNA (Lower
et al, 1996). HERV genomes are transmitted as part of the
host’s normal genetic material. Thus, the selective pressure
to maintain functional open reading frames (ORF) for viral
replication no longer applies. The maintenance of an HERV
Figure 5
Recombinant Skin ASpartic Protease
(rSASPase) auto-activation of wild-type
and mutated forms. The auto-activation
reaction was performed in 0.1 M acetate
pH 5 at 371C and monitored by SDS-
PAGE. (A) Lanes 1–7 incubation time 0, 5,
10, 20, 30, 80, and 120 min for wild-type
(wt) SASPase. Note: In this experiment,
rSASPase fusion protein batch is contam-
inated with an equivalent quantity of free
GST possibly due to an uncontrolled au-
to-activation occurring during the prepa-
ration process. (B) Comparison of auto-
activation of wt with mutated SASPase
(Active site aspartic acid (D) was either
replaced by alanine (A: D212A) or glut-
amic acid (E: D212E)) after 60 min of in-
cubation. The mutated forms have lost the
autocatalytic property. Arrow on the left
indicates the 14 kDa activated form. (C) A
proposed model of SASPase structure.
The putative complete protein (SASP37
343 aa, 37.0 kDa, pI 5.3) is represented
with the location of its putative trans-
membrane sequence, the predicted re-
troviral aspartyl protease signature, and
the primary auto-activation sites. The al-
ternative short form is named SASP28
(259 aa, 28.5 kDa, pI 5.22). The major au-
to-activation protease product is called
SASP14 (136 aa, 14.8 kDa, pI 5.2).
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ORF over a significant evolutionary time period suggests a
biological function (Patience et al, 1997) and indeed, mam-
malian proteins containing HERV sequences have been de-
scribed (Johansen et al, 1989; Lower et al, 1996; Benit et al,
1999). SASPase, a protease with a very high expression
level in human skin, is unique in the sense that it contains
several of the above-described features: (i) SASPase is
likely to be an HERV-derived protein based on its sequence
homology with viral proteases (data not shown) and (ii) SAS-
Pase auto-catalyzes the generation of proteolytic fragments
from a precursor fusion protein, which, after dimerization,
generates the active enzyme. This mechanism is strikingly
similar to that described for the HIV protease (Meek et al,
1989). Proteases sequences, highly conserved from rodents
to humans, served as a basis for Puente et al (2003) to
perform a bio-informatic search within the mouse and hu-
man genome. By this approach, five new members of the
human aspartic protease family were identified, some of
them presenting in addition to the retroviral aspartic pro-
tease signature, a DNA damage-inducible (DDI) signature,
responsible for SASPase designation in this study as DDI-
related proteins (DDI-rp). Moreover, we can consider that
the high conservation between mouse and human SASPase
orthologs implies that this protein is likely to have an indis-
pensable function.
It was also interesting to observe that the classical
aspartic protease inhibitor pepstatine, even at a concen-
tration of 1 mM, did not affect SASPase auto-activation,
indicating that SASPase is not only a new but also a very
particular member of the aspartic protease family.
The similarities described above between SASPase and
HIV protease and the fact that therapeutics target HIV pro-
tease (Kohl et al, 1988; Kay and Dunn, 1990; Dunn et al,
2002) prompted us to investigate possible interactions of
these inhibitors with SASPase. Among the four evaluated
therapeutic HIV protease inhibitors, only indinavir inhibited
SASPase auto-activation. It is interesting to note that in-
dinavir is reported to have severe cutaneous side effects
(Ward et al, 2002) like paronychia, cheilitis, xerosis (Garcia-
Silva et al, 2000), dermatitis, dry lips, hair loss, and nail
dystrophy (Carr et al, 1998; Calista and Boschini, 2000;
Harry et al, 2000). Recently, an indinavir–calpain interaction
was proposed to explain the skin manifestations induced
by indinavir (Ghibelli et al, 2003); however, inhibition of SA-
SPase might also account for some of the observed ad-
verse effects and even shed some light on its physiological
role in skin which has yet to be identified.
The adverse in vivo effects of indinavir have also been
described as ‘‘retinoid-like’’ effects (Bouscarat et al, 1998;
Toma et al, 2001; Garcia-Silva et al, 2002) and apparently,
indinavir is able to stimulate retinoid signaling in vitro (Len-
hard et al, 2000). Carr and collaborators (Carr et al, 1998)
observed that the catalytic region of HIV-1 PR, to which
protease inhibitors bind, has about 60% homology with re-
gions located within two proteins known to regulate ep-
idermal differentiation and lipid metabolism, the cellular
retinoic acid-binding protein 1 (CRABP-1), and the low
density lipoprotein-receptor-related protein (LRP), respec-
tively. It is noteworthy that a comparison of the complete
HIV-1 PR and SASPase sequence reveals a much better
alignment than that observed between the viral protease
and CRABP-1 or LRP. This observation reinforces interest in
studying how far indinavir–SASPase interactions might be
responsible for side effects observed during antiviral ther-
apies with this agent.
Another open question that remains is the identification
of SASPase substrates. Based on a certain homology be-
tween SASPase and retroviral proteases, substrates for the
latter enzyme family might give some indication of endog-
enous SASPase targets. Among the non-viral protein subst-
rates described for retroviral proteases are vimentin, desmin
(Shoeman et al, 1990), lactate dehydrogenase (Tomaszek
et al, 1992), calmodulin (Tomasselli et al, 1991), actin,
troponin C, Alzheimer amyloid precursor protein, and pro-
interleukin 1B (Tomasselli et al, 1991).
To speculate on the possible physiological role of SA-
SPase, we performed a screen within the MEROPS data-
base to identify proteases cleaving the same peptide bonds
as SASPase (data not shown). Besides retroviral-type
proteases, proteases with well-described physiological
functions in the skin were extracted from the database,
e.g., SCCE implicated in desquamation, MMP1, 3 (affecting
wound healing), thrombin (regulating the activation of the
protease-activated receptors) and convertase 3 (processing
filaggrin and other differentiation-related processes).
All these observations strengthen the idea that SASPase
might play an important role in cutaneous physiology. The
highly conserved status of SASPase throughout mammalian
and rodent evolution, its tight transcription regulation, and
elevated expression level in skin are good reasons for us to
further investigate its physiological role in the skin. The in-
dication that SASPase could represent an undesired target
of some HIV protease inhibitors as well as the possibility
that this human-retroviral chimeric protein could have other
as yet undiscovered interactions with the viral world makes
it an interesting target for further investigations.
Figure 6
Indinavir as an inhibitor of Skin ASpartic Protease (SASPase) auto-
activation. Recombinant fusion protein (1 mg per mL in Tris buffer
saline) was initially acidified to pH 5 with 1 M acetate buffer pH 4.5.
Stock solutions of 10 mM inhibitors in DMSO (N, norvir; R, ritonavir; A,
amprenavir; P, pepstatine; S, saquinavir) or in water (I, indinavir) were
used to bring the test solution to 0.1 or 1 mM final concentrations. A
control (C) was run without inhibitors. The final concentration of DMSO
was 10% in each case. Samples from the 0 and 30 min timepoints after
the initial acidification step were run on Nu-PAGE 12% gels in MES
buffer. The black arrow indicates the fusion protein, which is progres-
sively degraded to activated SASPase or SASP14 (dotted arrow).
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Material and Methods
Materials Isopropyl-1-thio-b-D-galactopyranoside, CHAPS (3-[(3-
Cholamidopropyl) dimethylammonio]-1-propane-sulfonate), sin-
apinic acid, BS3, DAN, EPNP, glutathione-Sepharose matrix, and
Taq polymerase were purchased from Sigma (L’Isle d’Abeau,
France). Immobiline pH gradient (IPG) solution, IPG strips, pre-
made SDS-PAGE gels, Rainbow molecular weight markers, silver
staining kit, first-strand synthesis kit, E. coli strain BL21, pGEX-4T3
plasmid and ECL advance kit, premade SDS-PAGE gelbond PAG
film-supported gels for horizontal electrophoresis, HiTrap and gel
filtration G75 HR10/30 column were from Amersham Pharmacia
Biotech (Saclay, France). RNase, DNase, thrombin, Taq polym-
erase, pfu polymerase, and restriction enzymes were from Prome-
ga (Lyon, France). The RNA preparation kit RNeasy was obtained
from Qiagen (Courtaboeuf, France). Oligonucleotides were syn-
thesized by Genset (Evry, France), and PCR-ready cDNA kits were
from Maxim Biotech. Site-directed mutagenesis kit was obtained
from Stratagene. Gelstar fluorescent stain was from Cambrex
(Verviers, Belgium). The HIV protease inhibitors norvir, ritonavir,
amprenavir, saquinavir, and indinavir were obtained from the NIH
AIDS Research and Reference Reagent Program.
2D electrophoresis and protein sequencing Reconstructed ep-
idermis after 13 d of culture (RE13D), obtained from Episkin (Lyon,
France) was used to prepare the epidermal protein extract (30
samples of RE13D, 1 cm2 each). Samples were immersed in 2.5
mL buffer (28 mM Tris-HCl, 22 mM Tris-base, containing 0.3%
SDS). The mixture was homogenized and boiled for 10 min. After
centrifugation (10,000  g for 10 min), the supernatant (2 mL) was
recovered and passed through a 0.22 mm membrane filter. Proteins
were precipitated by adding 10 mL of ice-cold acetone. After 20
min incubation, precipitated proteins were recovered by centrifu-
gation (9400  g for 10 min), dried at room temperature for 20 min,
and solubilized in 300 mL 2D buffer (8 M urea, 2% (wt/vol) CHAPS,
20 mM DTT and 0.5% (vol/vol) IPG solution pH 3-10).
Isoelectric focusing was performed using a Pharmacia Multi-
phor II system. One IPG strip, 18 cm, pH 3–10 was used according
to the manufacturer’s instructions. Horizontal SDS electrophoresis
was performed on pre-fabricated gelbond PAG film-supported gels
(12%–14% gradient) according to the manufacturer’s instructions.
For the second dimension, pre-stained molecular weight markers
were included after a 1:4 dilution. The apparent MW were calcu-
lated using Quantity one software from Bio-rad (Marnes la
Coquette, France). After staining the 2D gel with Amido Black,
the stained spots were recovered by performing 3 mm punch bi-
opsies. For protein identification, Edman sequencing was generally
used as previously described (Mehul et al, 2000). When necessary,
matrix-assisted laser desorption ionization time of flight (MALDI
TOF) or mass spectrometry (MS)/MS Q-TOF mass spectrometry
analyses were performed on samples desalted with Zip Tip C4
columns (Millipore, Guyancourt, France) on a Voyager STR MALDI
TOF apparatus from Perkin-Elmer (Courtaboeuf, France) or on an
ESI Q-TOF apparatus from Micromass (Waters, St Quentin-en-
Yvelines, France) at ESPCI (Ecole Supe´rieure de Physique et de
Chimie Industrielle de la ville de Paris).
SASPase putative 3D structure The program 3D-PSSM (http://
www.sbg.bio.ic.ac.uk/  3dpssm/) was used to calculate the pu-
tative 3D structure of SASP14. The EIAV protease structure was
used as a template for the simulation (d1fmb pdb file).
Northern blot analysis An mRNA blot for human adult tissues
was purchased from Origene (HB-1102, HB-2010) and used ac-
cording to the instructions. The selected probe was a 1026 bp
(human) SASPase cDNA fragment, which was digested from the
expressed sequence coding for SASP37 by using restriction en-
zymes EcoRI and BsmbI. Labeled cDNA probes were synthesized
by using the Rediprime random primer labeling kit (Amersham
Pharmacia) and 25 ng of the purified insert was used according to
the manufacturer’s instructions. 32P-labeled nucleotides were pur-
chased from Amersham Pharmacia.
Preparation of antibodies, immunohistochemistry, and west-
ern blot The monoclonal antibody SASP7H9 was developed at
CovalAb (Lyon, France). Briefly, mice were immunized with both a
gel filtration-purified SASP14 form and a denatured form within
acrylamide gel obtained after its separation by SDS-PAGE. The
antibody was finally purified from culture supernatants using pro-
tein A Sepharose.
Immunolocalization studies were conducted on thin paraffin-
embedded sections (5 mm) from normal and diseased skin at Life-
Span BioSciences (Seattle, Washington). Antibody SASP7H9 was
used as the primary antibody (1.25 mg per mL), and the principal
detection system consisted of a Vector (Burlingame, California)
anti-mouse secondary (BA-2000) and a Vector ABC-AP kit (AK-
5000) with a Vector Red substrate kit (SK-5100), which was used to
produce a fuchsia-colored deposit. Tissues were also stained with
positive control antibodies (CD31 and vimentin) to ensure that the
tissue antigens were preserved and accessible for immunohisto-
chemical analysis. Only tissues that were positive for CD31 and
vimentin staining were selected for the study. The negative control
was sections incubated in the absence of the primary antibody.
For tissue expression analysis, samples of normal human
epidermis (obtained after plastic surgery), reconstructed epider-
mis (day 13), and stratum corneum from normal and psoriatic skin,
obtained as described before (Mehul et al, 2000), were homoge-
nized in 1  Laemmli buffer containing 2% SDS and 200 mM DTT.
The buffer/sample wt/vol ratios were 500 mL of buffer for 10 mg of
wet tissue weight and 500 mL of buffer for 5 mg of dry tissue
weight. Homogenization was performed with a polytron for 1 min,
and then the suspension was boiled for 10 min before centrifuga-
tion (10,000  g for 10 min). Proteins in the supernatant were
quantified using a Bio-Rad protein assay and samples were ad-
justed to a protein concentration of 1 mg per mL. Twenty micro-
liters (diluted 1:1 in 2  Laemmli buffer) were run on 12.5%
Criterion SDS-PAGE gels following the manufacturer’s instructions.
Proteins were transferred to a PVDF membrane (Immobilon P,
Millipore) and the rest of the western blot was run using a standard
procedure with the primary monoclonal antibody SASP7H9 diluted
1:2000 in buffer containing 1% milk. The bands were visualized
using the ECL advance substrate system (Amersham Pharmacia
Biotech) on a FluorSmax imager (Bio-Rad).
Isolation of SASPpase cDNA from human keratinocytes and
expression of rSASPase cDNA was cloned by RT-PCR. Total
RNA was obtained from reconstructed human epidermis. RNA was
prepared using an RNeasy kit (Qiagen). Briefly, two samples of
reconstructed epidermis (day 13) were homogenized in 300 mL of
lysis buffer (included in the kit) and the cell debris were removed
using a QIA shredder column. cDNA was produced from purified
total RNA (2 mg) using the First-Strand cDNA Synthesis Kit. One to
5 mL of generated first-strand cDNA, with NotI-d(T)18 as primer,
was directly used for PCR. cDNA fragments of 1135 bp coding the
full-length SASPase (SASP37: methionine 1—end) was amplified
by PCR using pfu polymerase and oligonucleotides SC140: 50-
taggatccatggggagcccaggggc-30 and SC131: 50-ttgaattctcagtgg-
gatagctcctgccgc-30, under the following conditions: 1 cycle for
2 min at 951C, 35 cycles (941C for 30 s, 651C for 30 s, 721C for 2
min), and 1 cycle at 721C for 7 min. A cDNA fragment of 883 bp
coding for the truncated form (SASP28: methionine 85—end) was
amplified by PCR using pfu polymerase and oligonucleotides
SC131 and SC130: 50-gataggatccatggccgggagcggagccaggag-30,
under the same conditions as described for primers SC131/140.
These primers contained restriction sites (BamH1/EcoRI) to facil-
itate the incorporation of cDNA into a pGEX-4T3 plasmid. This
construct, containing an in-frame coding region for SASPase and
glutathion S-transferase, was used to transfect the E. coli strain
BL21(DE3). Expression and purification of rSASPase were per-
formed according to manufacturer’s instructions. Purified proteins
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were pooled, and buffer was changed using G25 gel filtration to 50
mM Tris-HCl, pH 8, containing 75 mM NaCl, 50% glycerol (SB).
Protein was maintained at 41C before use or at 201C for long-
term storage. If not indicated otherwise, the term rSASPase refers
to the GST-SASP28 fusion protein.
Autocatalytic properties of SASPase rSASP (3 mg per mL) in SB
was rapidly acidified at pH 5 by 1 M acetate buffer pH 4.5 and then
incubated at 371C. 10 mL aliquots were recovered at different times
during the incubation step and the reaction was stopped by ad-
dition of 10 mL Laemmli buffer. All the aliquots were analyzed
by SDS-PAGE on 12.5% acrylamide criterion gels following the
manufacturer’s instructions. Pre-stained Rainbow molecular
weight markers served as standards and molecular weights were
calculated using the Quantity-one software (Bio-Rad).
Site-directed mutagenesis The active site aspartic acid (D212)
was replaced either by glutamic acid (E: mutant D212E) or by ala-
nine (A: mutant D212A) using Site-directed Mutagenesis with the
quick change kit from Stratagene. The primers used for amplifi-
cation of the mutated SASPase were 50-gaggttcctggtggagtctgggg
cccaggtctctg-30 forward primer and 50-cagagacctgggccccagactc
caccaggaacctca-30 reverse primer for mutant D212E and 50-gag
gttcctggtggcctctggggcccaggtctctg-30 forward primer and 50-cag
agacctgggccccagaggccaccaggaacctca-30 reverse primer for mu-
tant D212A. The template used for PCR was the rSASPase con-
struct (SASP28) in pGEX-4T3. Competent cells (XL1 blue bacteria)
were transformed with the PCR product and selected clones were
sequenced to control for the presence of the mutation. The pro-
duction and purification of mutant proteins were then conducted
following the same protocols as for the wild-type form. The auto-
activation test reactions of wild-type and mutated forms of
SASPase were performed and monitored by SDS-PAGE as
described above.
HIV protease inhibitors and SASPase rSASPase (1 mg per mL in
SB) was initially acidified to pH 5 with 1 M acetate buffer pH 4.5.
Norvir, ritonavir, amprenavir, pepstatine, saquinavir in DMSO, and
indinavir in MilliQ water (10 mM stock solutions) were used to bring
the test solutions to either 0.1 mM or 1 mM. A control was run
without inhibitors. The final concentration of DMSO in each sam-
ple, including indinavir sample, was 10%. Nu-PAGE 12% gels (In-
vitrogen) were run with MES buffer just after the initial acidification
step and after 30 min incubation. The gel was finally stained with a
pre-made Coomassie solution (Bio-Rad) following the manufac-
turer’s instructions.
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